Cinclus Pharma Holding (CINPHA) Stock Overview
A clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CINPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cinclus Pharma Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 19.20 |
| 52 Week High | SEK 23.50 |
| 52 Week Low | SEK 9.31 |
| Beta | 0 |
| 1 Month Change | 12.94% |
| 3 Month Change | 13.61% |
| 1 Year Change | -16.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.11% |
Recent News & Updates
Recent updates
PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally
Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.Here's Why We're Not Too Worried About Cinclus Pharma Holding's (STO:CINPHA) Cash Burn Situation
Aug 19
Cinclus Pharma Holding (STO:CINPHA) Is In A Good Position To Deliver On Growth Plans
Dec 22Shareholder Returns
| CINPHA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 3.2% | 1.4% | 0.9% |
| 1Y | -16.2% | -3.6% | 6.7% |
Return vs Industry: CINPHA underperformed the Swedish Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: CINPHA underperformed the Swedish Market which returned 6.7% over the past year.
Price Volatility
| CINPHA volatility | |
|---|---|
| CINPHA Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: CINPHA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CINPHA's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 19 | Christer Ahlberg | cincluspharma.com |
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori).
Cinclus Pharma Holding AB (publ) Fundamentals Summary
| CINPHA fundamental statistics | |
|---|---|
| Market cap | SEK 893.53m |
| Earnings (TTM) | -SEK 177.05m |
| Revenue (TTM) | SEK 48.42m |
Is CINPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CINPHA income statement (TTM) | |
|---|---|
| Revenue | SEK 48.42m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 48.42m |
| Other Expenses | SEK 225.47m |
| Earnings | -SEK 177.05m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 18, 2026
| Earnings per share (EPS) | -3.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -365.66% |
| Debt/Equity Ratio | 0% |
How did CINPHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 12:17 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cinclus Pharma Holding AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |
| Damien Choplain | Stifel, Equities Research |
| Oscar Haffen Lamm | Stifel, Equities Research |